SEIZE THE $50 BILLION SITE-OF-CARE SHIFT OPPORTUNITY
Get the tools, data, and insights to drive growth.
Learn more
RECALIBRATE YOUR HEALTHCARE STRATEGY
Learn 4 strategic pivots for 2025 and beyond.
Learn more

Daily Briefing

Around the nation: Johnson & Johnson sues Biden administration over drug pricing negotiations


Johnson & Johnson (J&J) on Tuesday became the fourth drugmaker to file a lawsuit aimed at halting the Medicare drug pricing negotiation provisions within the Inflation Reduction Act, in today's bite-sized hospital and health industry news from Illinois, Minnesota, and New Jersey.

 

  • Illinois: Tina Freese Decker, president and CEO of Corewell Health, has been nominated to chair the American Hospital Association. Decker will succeed current chair Joanne Conroy, Dartmouth Health's president and CEO, in 2025. (Walsh, Modern Healthcare, 7/17)
  • Minnesota: Allina Health on Monday announced plans to lay off around 350 workers. The layoffs are system-wide, affecting multiple facilities, including Mercy and United Hospitals, according to internal communications. The health system, which employs over 28,000 individuals in both full- and part-time positions, cited mounting financial challenges as the primary reason, including high costs for supplies and labor, coupled with reduced payments for care services. The layoffs mostly involve leadership and non-direct caregiving roles. Affected employees will be offered severance and health benefits, along with outplacement resources. (Wiley, MPR News, 7/17)
  • New Jersey: J&J on Tuesday became the third fourth drugmaker to file a lawsuit aimed at halting the Medicare drug pricing negotiation provisions within the Inflation Reduction Act. J&J, which owns the pharmaceutical company Janssen, claims the law is unconstitutional and leaves Janssen with no choice but to remove all of its products from Medicare and Medicaid if it wants to avoid negotiations. "That provision is the legal equivalent of a gun to the head because it would require the manufacturer to give up access to nearly 40% of the U.S. health care market," J&J said. J&J also objected to signing contracts characterizing the negotiated price as "fair" under its First Amendment rights. Merck, Bristol Myers Squibb, PhRMA, and the U.S. Chamber of Commerce have also filed suits against the law. (Reed, Axios, 7/18; Cohrs, STAT+ [subscription required], 7/18)

SPONSORED BY

INTENDED AUDIENCE

AFTER YOU READ THIS

AUTHORS

TOPICS

INDUSTRY SECTORS

RELATED RESOURCES

Don't miss out on the latest Advisory Board insights

Create your free account to access 1 resource, including the latest research and webinars.

Want access without creating an account?

   

You have 1 free members-only resource remaining this month.

1 free members-only resources remaining

1 free members-only resources remaining

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
AB
Thank you! Your updates have been made successfully.
Oh no! There was a problem with your request.
Error in form submission. Please try again.